Abstract
The past 15 years have seen rapid advances in both our understanding of hereditary melanoma genetics and the technologies that enable scientists to make discoveries. Despite great efforts by many groups worldwide, other high-risk melanoma loci besides CDKN2A still remain elusive. A panel of polymorphisms that appears to confer low-to-moderate risk for melanoma has been assembled through functional and genome-wide association studies. The goal of personalized melanoma risk prediction is within our reach, although true clinical use has yet to be established.
Original language | English (US) |
---|---|
Pages (from-to) | 415-429 |
Number of pages | 15 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 23 |
Issue number | 3 |
DOIs | |
State | Published - Jun 1 2009 |
Keywords
- CDKN2A
- Genetics
- Germline mutations
- Melanoma
- Polymorphism
ASJC Scopus subject areas
- Hematology
- Oncology